Silence Therapeutics News

Silence Therapeutics Analyst Ratings

BenzingaApr 22 13:29 ET

Silence Therapeutics Analyst Ratings

BenzingaMar 15 12:55 ET

Silence Therapeutics Analyst Ratings

BenzingaMar 14 12:32 ET

Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating

MT NewswiresMar 14 07:57 ET

Silence Therapeutics Analyst Ratings

BenzingaMar 13 11:33 ET

Bullish on Silence Therapeutics: Buy Rating Affirmed Amid Strong Phase 2 Results for Zerlasiran

TipRanksMar 13 10:55 ET

Silence Therapeutics Analyst Ratings

BenzingaFeb 22 09:02 ET

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)

TipRanksFeb 22 06:30 ET

Analysts Offer Insights on Healthcare Companies: Healthcare Services (HCSG), Gritstone Oncology (GRTS) and Silence Therapeutics (SLN)

TipRanksFeb 13 07:30 ET

Silence Therapeutics Analyst Ratings

BenzingaJan 31 05:58 ET

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Silence Therapeutics (SLN) and Dyne Therapeutics (DYN)

TipRanksJan 31 01:00 ET

Buy Rating for Silence Therapeutics: Strong Prospects for RNAi Platform and Drug Candidates

TipRanksJan 22 15:35 ET

Silence Therapeutics Analyst Ratings

BenzingaJan 18 06:07 ET

Solid Financial Status and Promising Clinical Trial Results Drive Buy Rating for Silence Therapeutics

TipRanksNov 26, 2023 22:05 ET

HC Wainwright & Co. Maintains Buy on Silence Therapeutics, Lowers Price Target to $75

BenzingaNov 17, 2023 06:20 ET

Silence Therapeutics Analyst Ratings

BenzingaNov 17, 2023 06:18 ET

Promising Outcomes From Silence Therapeutics' SLN360 Drug Trials Bolster Buy Rating Recommendation

TipRanksNov 2, 2023 01:59 ET

Positive Phase I APOLLO Study Results Bolster Buy Rating for Silence Therapeutics

TipRanksNov 1, 2023 14:25 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Silence Therapeutics (SLN) and Monopar Therapeutics Inc (MNPR)

TipRanksNov 1, 2023 09:00 ET

Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price Target

BenzingaAug 17, 2023 07:47 ET